XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.1
Significant Agreements - Additional Information (Detail) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
May 26, 2021
Feb. 10, 2021
Dec. 16, 2019
Feb. 28, 2021
Mar. 31, 2023
Dec. 31, 2022
Takeda Asset Agreement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Upfront of cash payment     $ 1,000      
Takeda Asset Agreement [Member] | Common Stock            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Issuance of Series B redeemable convertible preferred shares for cash, net of issuance costs, shares 6,470,382          
Takeda Asset Agreement [Member] | Series A Redeemable Convertible Preferred Stock [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Stock Issued During Period, Shares, New Issues     9,857,143      
Stock Issued During Period, Value, New Issues     $ 9,900      
Issuance of Series B redeemable convertible preferred shares for cash, net of issuance costs, shares 9,857,143          
Takeda Asset Agreement [Member] | Research And Development Expense            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Upfront payment   $ 8,000        
Merck License Agreement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Payment of Milestones         $ 0  
Merck License Agreement [Member] | Research And Development Expense            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Payment of Milestones           $ 2,500
Merck License Agreement [Member] | Research And Development Expense | Maximum [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payments not yet paid         $ 364,500  
Viracta License Agreement [Member] | Maximum [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Milestone payments not yet paid       $ 54,000    
Viracta License Agreement [Member] | Research And Development Expense            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Payment of Milestones       $ 3,000    
Upfront of cash payment     $ 2,000